ReviewTuberculosis and respiratory diseases2016
Tuberculosis Infection and Latent Tuberculosis.
Review in Tuberculosis and respiratory diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Immune dysregulation in tuberculosis-diabetes comorbidity: mechanistic and translational insights.Frontiers in immunology · 2026Pooled it
- Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review.BMC infectious diseases · 2025Pooled it
- Epidemiology of TB in prisoners: a metanalysis of the prevalence of active and latent TB.BMC infectious diseases · 2023Pooled it
- Meta-analysis of active tuberculosis gene expression ascertains host directed drug targets.Frontiers in cellular and infection microbiology · 2022Pooled it
- Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations.The Cochrane database of systematic reviews · 2019Pooled it
- Integrative multi-omics analysis identifies SELL and PRF1 as key immune biomarkers and therapeutic targets in tuberculosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Role of the PTPN22 C1858T (R263Q) variant in tuberculosis susceptibility: genetic and functional evidence from a South Asian cohort.BMC medical genomics · 2026Article
- Mechanisms ofBreathe (Sheffield, England) · 2026Review
- IL-5 and IP-10 Detected in Quantiferon Supernatants Distinguish Latent Tuberculosis from Healthy Individuals in Areas with High Burden in Lima, Peru.Pathogens (Basel, Switzerland) · 2025Article
- Coinfections in Tuberculosis in Low- and Middle-Income Countries: Epidemiology, Clinical Implications, Diagnostic Challenges, and Management Strategies-A Narrative Review.Journal of clinical medicine · 2025Review
- Risk of malignant lymphoma in patients with previous tuberculosis infection: a cohort study.Annals of hematology · 2025Article
- An integrative and comprehensive analysis of blood transcriptomes combined with machine learning models reveals key signatures for tuberculosis diagnosis and risk stratification.Frontiers in microbiology · 2025Article
- Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study.Tropical diseases, travel medicine and vaccines · 2024Article
- Differential Epigenetic Regulation in Uninfected and Tuberculosis-Human Immunodeficiency Virus Co-Infected Patients.Microorganisms · 2024Article
- 3,5-disubstituted pyridines with potent activity against drug-resistantFuture medicinal chemistry · 2024Article
- Current development of therapeutic vaccines for the treatment of chronic infectious diseases.Clinical and experimental vaccine research · 2024Review
- Multi-target Compounds against Trypanosomatid Parasites andCurrent drug targets · 2024Review
- Antigen-Induced IL-1RA Production Discriminates Active and Latent Tuberculosis Infection.Microorganisms · 2023Article
- Exploring biogenic chalcones as DprE1 inhibitors for antitubercular activity via in silico approach.Journal of molecular modeling · 2023Article
- Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active tuberculosis (TB) has a greater burden of TB bacilli than latent TB and acts as an infection source for contacts. Latent tuberculosis infection (LTBI) is the state in which humans are infected with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.